Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024. In the quarter to June 2026, revenue grew 13.0%, EPS fell 47.5%, free cash flow grew 28.9% and total debt rose 142.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

104.88 0.20 +0.19%
Market cap
$181.1B
P/E
33.9×
Fwd P/E
22.9×
Dividend yield
2.40%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
29.37 28.76 33.68 16.78

+8 more quarters

P/S ratio
3.39 3.96 4.92 5.32
P/FCF ratio
20.18 24.25 29.50 33.73
P/Operating CF
63.48 136.05 65.80 83.73
P/B ratio
3.05 3.39 4.13 4.55
EV/Sales
3.97 4.56 5.01 5.44
EV/EBITDA
17.14 18.92 19.89 22.00
EV/FCF
23.64 27.87 30.04 34.49
Current Ratio
1.38 1.39 1.58 1.70
Net Debt/EBITDA
9.81 12.45 1.31 1.83
Debt/Equity
0.63 0.65 0.25 0.25
Earnings Yield
3.41% 3.48% 2.97% 5.96%
Free Cash Flow Yield
4.95% 4.12% 3.39% 2.96%
Free Cash Flow per Share
1.14 0.53 1.51 1.32
Book value per Share
29.74 30.24 30.31 29.43
Free Cash Flow
1,991.00 916.00 2,626.00 2,291.00
EV/EBIT
25.17 26.69 27.58 30.93
Other line items

Show all line items

Columns are period end dates